Novo Nordisk (NVO -1.69%), known for its GLP-1 weight loss drugs Ozempic and Wegovy, saw a 2% decline after Reuters reported weak U.S. prescription data, raising concerns about its growth potential. Following this, DBS Bank downgraded its rating from “buy” to “sell,” setting a price target of 330 Danish krone (approximately $50.28), which is 18% lower than its current trading price. Despite this, some analysts believe the stock may be undervalued at 18.2 times earnings, suggesting it could be a good buying opportunity amid negative sentiment.
